Back to Trials
NCT07152002PHASE1RecruitingAccepts Healthy Volunteers

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

Eli Lilly and Company

Start Date

8/28/2025

Completion Date

11/1/2026

Summary

The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Eligibility Criteria

Age Range: 18 years to 65 years

Inclusion Criteria: * Age is 21-65 years old at Singapore Sites * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring Part A: Body Mass Index (BMI) within the range greater than or equal to 21 and less than 30 kilogram per square meter (kg/m²) Part B: a BMI greater than or equal to 27 and less than 45 kg/m² Part C: a BMI greater than or equal to 21 and less than 35 kg/m² * Parts A and C: Participants must weigh 60 kilograms (kg) or more at screening * Have had a less than 5% change in body weight for 3 months before screening * Safety laboratory tests are within normal reference range Exclusion Criteria: * Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data * Have history of diabetes (except gestational diabetes) or current diagnosis of diabetes (any form), or have HbA1c greater than or equal to 6.5% (48 millimole per mole (mmol/mol)) at screening * Are individuals of childbearing potential (IOCBP).

Interventions

DRUG

LY4064912

DRUG

LY4064912

DRUG

Placebo

DRUG

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Overweight or ObesityHealthy

Locations

Collaborative Neuroscience Network - CNS

Los Alamitos, California 90720

United States

ICON Early Phase Services

San Antonio, Texas 78209

United States

Lilly Centre for Clinical Pharmacology

Singapore, 138623

Singapore